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Background: Influenza virus has antigen drift and antigen shift effect, vaccination with some influenza vaccine
might not induce sufficient immunity for host to the threat of other influenza virus strains. S-OIV H1N1 and H5N1
influenza vaccines in single-dose immunization were evaluated in mice for cross protection to the challenge of
A/California/7/2009 H1N1 or NIBRG-14 H5N1 virus.
Results: Both H1N1 and H5N1 induced significant homologous IgG, HAI, and microneutralization antibody
responses in the mice, while only vaccines plus adjuvant produced significant heterogeneous IgG and HAI antibody
responses. Both alum and MPLA adjuvants significantly reduced the S-OIV H1N1 vaccine dose required to elicit
protective HAI antibody titers from 0.05 μg to 0.001 μg. Vaccines alone did not protect mice from challenge with
heterogeneous influenza virus, while H5N1 vaccine plus alum and MPLA adjuvants did. Mouse body weight loss
was also less significant in the presence of adjuvant than in the vaccine without adjuvant. Furthermore, both H1N1
and H5N1 lung viral titers of immunized mice were significantly reduced post challenge with homologous viruses.
Conclusion: Only in the presence of MPLA adjuvant could the H5N1 vaccine significantly reduce mouse lung viral
titers post H1N1 virus challenge, and not vice versa. MPLA adjuvant induced cross protection with a single dose
vaccination to the challenge of heterogeneous influenza virus in mice. Lung viral titer seemed to be a better
indicator compared to IgG, neutralization antibody, and HAI titer to predict survival of mice infected with influenza
virus.
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The swine-original influenza virus A (S-OIV) H1N1 was
determined to be a novel strain of A/Influenza H1N1
serotype which had been derived by reassortment of
swine, avian and human influenza viruses. The WHO
declared that the infections caused by the new strain
had reached pandemic proportions on June, 2009; and
has reported approx. 14700 deaths in more than 209
countries resulting from pandemic influenza H1N1 [1].* Correspondence: yeauching@mail.ndmctsgh.edu.tw
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reproduction in any medium, provided the orImmunization provides the best preventive strategy
against influenza virus illness. The current trivalent vac-
cine is unlikely to provide significant protection against
the novel pandemic H1N1 strain, especially for children
and young adults because of absence or low immunity to
the novel 2009 H1N1 strains [2,3]. It has been reported
that previous vaccination of children with trivalent vaccine
of the last four seasons did not elicit a cross-reactive anti-
body response to the pandemic H1N1 strain [4]. Thus, a
monovalent vaccine based on the novel H1N1 strain will
be required to induce protective immunity.
Current influenza virus vaccines aim to induce strong
antibody (Ab) responses to the ectodomains of hemag-
glutinin (HA) and neuraminidase (NA) molecules, since. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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against infection and/or disease. The main deficiency of
this protection is that it targets highly variable viral de-
terminants. Failure to anticipate the emergence of an
epidemic strain with significant antigenic changes com-
pared to the vaccine strain will greatly reduce vaccine-
induced protection. Several studies have suggested that
proper adjuvant might improve the immunity of influ-
enza vaccine and reduce the dose of vaccine [5-10].
Aluminum hydroxide (alum) is currently the only
human vaccine adjuvant approved for use in the United
States, and although it is effective at boosting antibody
responses, these responses require repeated administra-
tion and tend to generate antiparasitic T helper 2 (TH2),
rather than antiviral and antibacterial TH1, T cell im-
munity [11]. As a consequence, there is much effort de-
voted to develop prospective adjuvant that can establish
protective immunity with fewer vaccinations and less
injected material, through durable antibody and TH1-
dependent cytotoxic T cell activity. Other potential
immune adjuvant might be considered and developed.
As demonstrated previously, Monophosphoryl lipid A
(MPLA) is a low-toxicity derivative of LPS with useful
immunostimulatory properties, which is nearing regula-
tory approval for use as a human vaccine adjuvant. Most
recently, it has been demonstrated that the use of Al
(OH)3 with MPLA as an emulsion induced a further
increase in HAI titers of A/reassortant/NIBRG-14/Viet
Nam 1194/2004 × Puerto Rico/8/1934 H5N1 (NIBRG-
14) inactivated whole virus and split virion influenza
vaccines [12]. These finding may have important impli-
cations for the development of future vaccine adjuvant.
Although there are studies evaluating immune re-
sponse and protection of influenza H1N1 vaccine to
2009 S-OIV in ferrets and mice most recently [13-16].
Some studies also approached immune response and
protection of vaccinated animals against other influenza
virus in the absence or the presence of adjuvant. In these
studies, some useful information has been revealed. For
example, pandemic H1N1 vaccination is effective in
mice [17]; the adjuvant MPLA can reduce the effective
immunization dose of H5N1 and H3N2 influenza vac-
cines in mice [18]; and some other adjuvant can reduce
the effective immunization dose of pandemic vaccines in
mice [19,20]. However, most of these studies focus on
the protection of BALB/c mice immunized in a two-
dose regimen of vaccination. Since it is impossible to
vaccinate people twice at the emergent time during in-
fluenza virus is pandemic worldwide, effective vaccine
component and dosage of influenza vaccine for single
immunization is more practical and critical for the pre-
vention of influenza virus epidemic. In this study, single-
dose immunization of 2009 H1N1 vaccine based on
NIBRG-121 vaccine strain and avian H5N1 vaccinebased on NIBRG-14 vaccine strain were evaluated for its
effectiveness to elicit protective immunity of mice to
the lethal challenge of A/California/07/2009 H1N1 virus.
Meanwhile, the minimum effective dose of single immu-
nization in the absence or the presence of adjuvant (either
alum or MPLA); as well as the cross protection of hetero-
geneous vaccine, the changes of adjuvant-induced im-
mune responses, and the reduction of vaccine dose used
in the presence of adjuvant were also elucidated.
Methods
Vaccine strains and reagents
Influenza A virus NIBRG-121 (NIBSC, A/California/
7/2009 H1N1 virus), virus (A/California/07/2009 H1N1;
CDC# 2009712112), hemagglutinin (HA) antigen
(A/California/7/2009, NIBSC 09/146), and antiserum
(A/California/7/2009, NIBSC 09/152) were obtained
from the Centers for Disease Control and Prevention
(CDC, Taiwan), or the National Institute for Biological
Standards and Control (NIBSC, UK). NIBRG-121 was
used as vaccine strain, and virus A/California/07/2009
H1N1 was used as challenge virus.
Vaccine production
NIBRG-121 virus strain was amplified in embryonic eggs
of 10-day special pathogen free (SPF) for 48 h, it was
then harvested and inactivated with 0.04% formalin at
4°C for overnight. Harvested virus was then filtered
through 0.45 μm filter and concentrated with Lab scale
TM TFF System, treatment with benzonase (cat. no.
1.01656.0001, Merck KGaA, Germany) (9 ~ 90 u/ml at
4°C for overnight), and purified with 10-50% sucrose
gradient by Alfa Wassermann PKII Pilot-Scale Ultracen-
trifuge System. Purified virus was dialyzed with PBS,
filtered with 0.45 μm filter and stocked in 1.5-ml stock
tube at −80°C until use. Hemagglutinin (HA) antigen
concentration was determined by single radial immuno-
diffusion assay (SRD) [21] for the quantification of vac-
cine S-OIV H1N1.
Quality control assays of vaccine
To monitor the quality of produced vaccine, several
items of assays were evaluated. Vaccine was quantified
with SRD method; ovalbumin was evaluated with
Chicken Egg Ovalbumin Elisa Kit (Cat. No. 6050) from
Alpha Diagnostic International (ADI); endotoxin was
measured with Toxin Sensor TM Chromogenic LAL
Endotoxin Assay Kit (Cat. No. L00350) obtained from
the GenScript Corporation. Above assays were followed
the protocols of commercial kits. Formalin content of
vaccine was evaluated according to the guideline of ver-
sion 6th of Pharmacopoeia Chinensis. For abnormal tox-
icity assay, male BALB/c mice (body weight: 17–22 gm)
were inoculated intraperitoneal with 0.5 ml of produced
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observed their changes of body weight. It fit the demand
criteria only if there is no death, accident symptoms of
mice, and mice should recovery of their body weight to
the level of pre-inoculation 7 days after inoculation. The
antigenicity of vaccine was evaluated with hemagglutination
(HA) assay as described with HAI assay without antibody.
Determination of vaccine HA concentration
The HA concentration of S-OIV candidate vaccine was
measured with single-radial immunodiffusion (SRD) ac-
cording the protocol described previously [22,23].
Ethics statement
All animal experiments were reviewed by the Institutional
Animal Care and Use Committee and approved by the
regulatory authorities of Taiwan. All animal experiments
were conducted in accordance with Taiwan laws on animal
experimentation and guidelines set out by the Association
for Assessment and Accreditation of Laboratory Animal
Care International (AAALAC) and the Office of Labora-
tory Animal Welfare (OLAW). The IACUC certificate
No. of this study were AN-99-05、 AN-100-07、 and
AN-101-06. Animal were housed according to OLAW
and AAALAC guidelines, in housing facilities accredited
by the Center of Disease Center (CDC) of Taiwan.
Immunization of mice
Female BALB/c mice (8-week-old) were immunized in-
traperitoneal with different dosage of produced vaccine
(PBS control, 0.001 μg, 0.01 μg, and 0.05 μg) in the ab-
sence or presence of adjuvant alum (final 5% of
Aluminum hydroxide gel, cat no.A8222, Sigma) or
MPLA (Monophosphoryl Lipid A) (Sigma Adjuvant Sys-
tem, cat no.S6322, Sigma) using a single-vaccination
regimen.
IgG subclass determination
ELISA plates were coated with 10 ng HA per well of
purified vaccine at 4°C for overnight. After blocking
nonspecific binding (5% skim milk in PBST, 1 h at 37°C)
and subsequent washing, PBST diluted mice sera (1:400)
of pre-immune or immunized were added to wells and
plated were incubated for 1 h at 37°C, washed again,
prior to further incubation for 1 h with IgG subclass-
specific peroxidase-conjugated goat or rabbit anti-mouse
IgG antibodies (IgG: goat anti-mouse IgG (H + L) HRP,
cat. no. 115-035-146, Jackson ImmunoResearch, USA;
IgG1: rabbit anti-mouse IgG1 HRP, cat. no. 61–0120,
Invitrogen, USA; IgG2b: rabbit anti-mouse IgG2a HRP,
cat. no.61-0220, Invitrogen, USA). Bound IgG subclass
antibodies were detected colorimetrically using TMB
substrate by OD450 nm endpoint reading. The cutoff
value was set at ODn plus three standard deviations,where ODn is the mean of ODs of six preimmune serum
specimens.
Cell and virus
MDCK (Madin-Darby canine kidney) cells were obtained
from the American Type Culture Collection (ATCC), and
maintained in Dulbecco’s minimum essential medium
(DMEM; GIBCO, Invitrogen, USA) supplemented with
100 U/ml of penicillin, 100 μg/ml of streptomycin and
10% fetal bovine serum (GIBCO, Invitrogen) at 37°C in a
humidified atmosphere with 5% CO2. Influenza A virus
NIBRG-121 (NIBSC, A/California/7/2009 H1N1 virus);
obtained from the CDC of Taiwan) was amplified in
10-day-old embryonic eggs at 35°C for 48 h. Virus was
harvested from allantoic fluid. To determine the LD50 of
each batch of virus, female BALB/c mice (6–7 weeks)
(n = 10/group) were anesthetized subcutaneously with
Zoletil 50 (Virbac Laboratories, France) (0.375 mg/mice)
and inoculated intranasally with serial dilutions of the
virus. The LD50 was the dilution of the virus that pro-
duced lethality in 50% of the mice and LD50 titers were
calculated by the method of Reed and Muench [24]. The
LD50 was over 10
5 TCID50 for NIBRG-121.
Plaque-assay
To measure virus titer, MDCK cells (5×106 /well) were
inoculated into 6-well microplates and were incubated at
37°C in a humidified atmosphere with 5% CO2 for over-
night. In the second day, a serial of 10-fold dilutions of
virus were prepared in PBS; MDCK cells were washed
two times with PBS and 100 μl of viral dilutions were in-
oculated into 6-well microplates for adsorption. After
one hour of adsorption, virus suspensions were removed
and cells were washed two times with PBS; then 1%
Oxoid agars in DMEM/BSA medium were inoculated
into microwells, microplates were incubated at 37°C in a
humidified atmosphere with 5% CO2 for three days.
MDCK cells were fixed with 10% formalin for 1 h, then
agars were removed and stained with crystal violet solu-
tion (0.5%) for 1 hour, stained cells were washed with
tap water and were observed. Microplates were air dried
at room temperature for several hours, and plaques were
calculated for virus concentration.
TCID50
To calculate virus titer, MDCK cells (1.5 × 104 /well) in
DMEM medium with 10% FBS were inoculated into
96-well microplates and were incubated at 37°C in a
humidified atmosphere with 5% CO2 for overnight. In
the second day, a serial of 10-fold dilutions of virus were
prepared in PBS; MDCK cells were washed two times
with PBS and 100 μl of viral dilutions were inoculated
into 96-well microplates for adsorption. After one hour
of adsorption, virus suspensions were removed and cells
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medium were inoculated into microwells, and microplates
were incubated at 37°C in a humidified atmosphere with
5% CO2 for additional five days. The TCID50 titers of virus
were calculated by the method of Reed and Muench [24].
Hemagglutination inhibition (HI) assay
Functional H1N1 HA-specific antibody titers were deter-
mined by HI assay using chicken erythrocytes. Prior to
serological analysis, sera were treated with receptor-
destroying enzyme (RDEII, Denka Seiken, Tokyo, Japan).
Serum (0.1 ml) was mixed with 0.3 ml receptor-destroying
enzyme, incubated at 37°C for 18 h, and adjusted to a final
1:10 dilution by adding PBS, and inactivated the enzyme
activity by incubation at 56°C for 30 min. Sera giving a
negative signal in the first dilution (1:10) were assigned a
nominal HI score of 1:5. HI titers are expressed as recipro-
cal value of the highest serum dilution that inhibited
hemagglutination. Animals with a serum HI titer of 1:40
were considered seroprotected.
Intranasal influenza challenge
Four weeks after immunization with S-OIV H1N1 or
NIBRG-14 H5N1 vaccine; immunized mice were blood-
letting for antibody assay and were then lightly
anaesthetized with Zoletil 50 (VIRBAC Laboratories,
France) and challenged intranasal with 1 × 106 TCID50
A/California/7/2009 H1N1 virus. Over the following
14 days, body weights and survival rates of each group
of mice were monitored daily.
Microneutralization assay
Neutralization antibodies of mice post vaccinated with
S-OIV H1N1 or NIBRG-14 H5N1 vaccines were evaluated
using microneutralization assay. Mice sera (pre-immune as
negative; A/California/7/2009 NIBSC 09/152 and anti-
serum to NIBRG-14 H5N1 HA as positive control) were
mixed with viruses (100 TCID50 of NIBRG-121 H1N1 or
NIBRG-14 H5N1 virus) at room temperature for 1 hour,
and were inoculate into 96-well MDCK cells (1.5 × 104/ml).
Experiment was performed following WHO protocol of
microneutralization assay [21,25].
Statistical analysis
In all figures, vertical error bars denote the standard
deviation (SD). Significances of differences in antibody
responses and cellular responses were evaluated by
one-way analysis of variance (ANOVA). T test was used
for the comparison of two specific groups in one-way
ANOVA. To test the significance of survival rates be-
tween each group of immunized mice, a Z’ (alternative
critical ratio) test was used [16,26]. For the comparison
of HAI antibody titer, Mann–Whitney U test was used.
A P value of < 0.05 was considered significant.Results and discussion
Production of S-OIV H1N1 and NIBRG-14 H5N1 vaccine
It is previously reported that a single candidate seasonal
H1N1 and H3N2 vaccine produced by an identical process
was highly immunogenic and protective in mammalian
(Vero) cells [17]. These studies were subsequently demon-
strated to be highly predictive of the immunogenicity
demonstrated in human trials, particularly with respect to
immunogenicity at low doses and the lack of immune en-
hancement by use of an alum based adjuvant [27]. No
clear cut correlate for protection has been established for
potential pandemic vaccines such as the H5N1 vaccine or
the novel H1N1 vaccine at present. Data obtained from
animal protection studies could be of value in combin-
ation with data obtained from human dose finding and
observational efficacy studies following vaccine use in a
pandemic situation such as presently exists for the novel
H1N1 virus. This study was designed to assess the im-
munogenicity and protective efficacy of S-OIV H1N1 and
NIBRG-14 H5N1 influenza vaccines to the challenge of
A/California/7/2009 H1N1 or NIBRG-14 H5N1 virus in a
BALB/c mice model with a single-dose immunization
regimen.
To produce a novel vaccine for S-OIV H1N1 and
NIBRG-14 H5N1, NIBRG-121 and NIBRG-14 virus
strains were amplified in 10-day special pathogen free
(SPF) embryonic chicken eggs for 48 h and were then
harvested. Viruses were inactivated with 0.04% formalin
(4°C, overnight) and were purified using the Alfa
Wassermann PKII Pilot-Scale Ultracentrifuge System
(Alfa Wassermann Inc. (AWI), USA) Hemagglutinin
(HA) antigen content was determined by single radial
immunodiffusion assay. Results showed that the S-OIV
H1N1 vaccine contained about 38 μg/ml of HA protein,
which was estimated to be equal to 1 to 1.5 doses of vac-
cine (15 μg HA was regarded as one dose) for each egg.
The vaccine produced was quality control tested and
characterized for antigenicity (HA titer, 128–256), ov-
albumin (≤ 4 μg/ml), formalin (0.373–0.548 μg/ml), and
endotoxin (28–51 EU/ml) (Table 1). All tested items of
vaccine produced had qualities fitting the vaccine criteria
of the international standard. Furthermore, two lots of
S-OIV H1N1 vaccine produced were tested for abnor-
mal toxicity in mice. The results showed no abnormal
toxicity in mice (data not shown). Results demonstrated
the S-OIV H1N1 vaccines produced conformed to the
quality control (QC) requirements of the World Health
Organization (WHO) and European criteria for influ-
enza vaccines. Some QC items of NIBRG-14 H5N1 vac-
cine did not conform to the international standard. The
candidate vaccines produced were used to evaluate their
protective immune effects in mice.
Single-dose immunization of S-OIV H1N1 or NIBRG-
14 H5N1 vaccine elicited a sufficient immune response
Table 1 Quality control of candidate S-OIV H1N1 and NIBRG-14 H5N1 vaccines
Test items Summary of results Notes
Abnormal toxicity S-OIV pass, H5N1 not done Body weight of tested mice increased
Antigenicity HAI titer: S-OIV 128 ~ 256 Also interacted with NIBSC sntisera
H5N1 1024
Endotoxin S-OIV Between 28 ~ 51, International criteria: ≤ 200 EU/ml
H5N1 31.4 EU/ml,
Ovalbumin S-OIV ≈ 4 μg/ml, Europe: ≤ 2 μg/ml; WHO: ≤ 5 μg/ml
H5N1 55 μg/ml
Formaldehyde S-OIV 0.373 ~ 0.548 μg/ml, WHO: ≤ 0.02% ~0.01% (≈1 mg/ml)
H5N1 not done
Note: Result showed that all items evaluated for quality control of produced candidate vaccine fit the demand of international criteria.
Figure 1 Immunization scheme of candidate S-OIV H1N1 and
avian H5N1 vaccine. BALB/c mice were immunized with different
doses of the produced vaccine S-OIV H1N1 or NIBRG-14 H5N1.
(A) PBS control, 0.001 μg, 0.01 μg, and 0.05 μg of S-OIV H1N1 or
NIBRG-14 H5N1 vaccine; (B) PBS control, 0.01 μg, and 0.05 μg of
S-OIV H1N1 or NIBRG-14 H5N1 with or without alum or MPLA
adjuvant. About 3 weeks after immunization, the mice were
challenged with 106 TCID50 of A/California/7/2009 H1N1 or 1000
TCID50 NIBRG-14 H5N1.
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respectively, in a dose-dependent manner in the mice.
In actual practical work, it seems impossible to vaccin-
ate people twice on an emergency basis during a
worldwide influenza virus pandemic. Effective vaccine
components and influenza vaccine dosage for single
immunization are more practical and critical for the pre-
vention of influenza virus epidemics. In this study, a
single-dose immunization of 2009 S-OIV (NIBRG-121)
H1N1 and NIBRG-14 H5N1 vaccine was evaluated
for its effectiveness to elicit protective and cross protect-
ive immunity in mice to the lethal challenge of
A/California/07/2009 H1N1 virus (Figure 1). First,
groups (10 mice per group) of mice were primed with
PBS or different doses (0.001 μg, 0.01 μg, and 0.05 μg)
of S-OIV H1N1 vaccine in the absence or presence of
alum or MPLA adjuvant in a single-dose immunization
regimen. The mice were then challenged with 106
TCID50 of A/California/07/2009 H1N1 virus 28th days
post vaccination (panel A). Second, the cross protection
of S-OIV H1N1 and NIBRG-14 H5N1 vaccines were
evaluated. As shown in Figure 1 panel B, the mice were
immunized with PBS, 0.01 μg, or 0.05 μg of S-OIV
H1N1 and NIBRG-14 H5N1 vaccines in the absence or
presence of alum or MPLA adjuvant in a single-dose
vaccination regimen. Mouse spleen and lungs were col-
lected 3 days post challenge with H5N1 or H1N1 virus,
respectively, and were used for microneutralization assay
and mice lung viral assays. As shown in Figure 2A and
2B, S-OIV H1N1 and NIBRG-14 H5N1 vaccines elicited
immune responses in a dose-dependent manner in the
mice.
Adjuvant promoted IgG responses to homologous S-OIV
H1N1 and NIBRG-14 H5N1 influenza viruses
The candidate vaccine elicited an immune response in a
dose-dependent manner in the mice. In the absence of
adjuvant, 0.05 μg of S-OIV H1N1 and NIBRG-14 H5N1
were required to elicit a significant antibody response.When either alum or MPLA adjuvants were included in
the vaccine, only 0.001 μg of S-OIV H1N1 (Figure 2A)
and NIBRG-14 H5N1 vaccine (Figure 2B) were needed
to significantly induce specific immune responses. The
NIBRG-14 H5N1 vaccine had better antigenicity than
the S-OIV H1N1 vaccine.
Figure 2 Adjuvant promoted strong protective immune responses to S-OIV H1N1 virus. To realize the least immunization dose of S-OIV
and H5N1 vaccine needed for mice to raise sufficient protective immune responses to A/California/7/2009 virus, mice (n = 7 to 8 per group)
immunized with PBS, 0.001 μg, 0.01 μg, or 0.05 μg of vaccine in the presence or absence of adjuvant. Three weeks after the single immunization,
mice sera were evaluated for (A) H1N1 IgG, (B) H5N1 IgG, and (C) H1N1 IgG1 and IgG2a, and (D) H5N1 IgG1 and IgG2a immune responses to
A/California/7/2009 virus. The data represent the mean titers ± SD (error bars) of antibodies in each group of animals.
Lin et al. Journal of Biomedical Science 2013, 20:19 Page 6 of 13
http://www.jbiomedsci.com/content/20/1/19Adjuvant improved S-OIV H1N1 vaccine to elicit a Th1-
type antibody response (IgG2a)
The effects of different adjuvants were compared for their
enhancement of immune response to influenza virus. Both
alum and MPLA adjuvants improved the S-OIV H1N1
vaccine IgG2a immune response, an indicator of cellular
immunity IgG antibody (Figure 2C). Alum adjuvant im-
proved both humoral and cellular immune responses,
while MPLA adjuvant improved the IgG2a immune re-
sponse; the IgG2a/IgG1 ratio increased from 7.926 (vaccine
alone) to 17.846 (vaccine plus MPLA) (Figure 2C). Contro-
versially, both alum and MPLA adjuvants were more ef-
fective in eliciting Th2-type antibody (IgG1) responses
than Th1 antibody (IgG2a) responses in mice immunized
with NIBRG-14 H5N1 vaccine (Figure 2D). Thus, a candi-
date vaccine containing adjuvant might be able to elicit
both humoral and cellular immune responses. Therefore,
an S-OIV H1N1 vaccine containing alum as the adjuvant
might be effective in preventing and eliminating an influ-
enza virus infection by eliciting both Th1 and Th2 immune
responses, while a vaccine containing MPLA as the adju-
vant would eliminate influenza virus by enhancing mainly
the Th1 immune response [6]. As shown in Figure 3A,alum and MPLA adjuvants enhanced mouse survival rates
post challenge after immunization with a single-dose vac-
cine. These data imply that MPLA is more suitable than
alum for use as an adjuvant for influenza vaccines. Another
study also implied that MPLA could reduce the minimum
effective immunization dosage of H5N1 and H3N2 influ-
enza vaccines in mice [18]. For H5N1 vaccines, both
alum and MPLA adjuvants effectively promoted Th2 anti-
body immune responses; they enhanced H5N1 vaccine-
immunized mouse Th1 immune response less effectively.
Adjuvant enhanced the vaccine’s hemagglutination
inhibition (HAI) antibody response
Since the HAI antibody titer is considered an effective
immunity indicator of host defense against influenza
virus, we evaluated the adjuvant-induced HAI antibody
response of the S-OIV H1N1 vaccine. Both alum and
MPLA adjuvants enhanced HAI antibody titers when in-
cluded in the 0.05-μg S-OIV H1N1 vaccine (P < 0.05)
(Figure 4). Furthermore, the dosage required for the
candidate S-OIV H1N1 vaccine to elicit production
of a protective HAI antibody response (HAI antibody
titer ≥ 40) was 0.05 μg. With this dosage, the positive
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ranged from 80 to 160. The required vaccine dosage in-
ducing a protective antibody response was reduced to
0.01 μg (average HAI titer of 80 to 320) or 0.001 μg
(average HAI titer of 80) when the vaccines were mixed
with alum or MPLA adjuvants, respectively. Similar re-
sults were also demonstrated in a study of H5N1
(NIBRG-14) inactivated whole virus and split virion
influenza vaccines, in which, the use of Al(OH)3 with
MPLA as an emulsion induced a further increase of
HAI titer [12]. This implies that the addition of an
adjuvant to the vaccine could reduce the vaccine dos-
age required to elicit a protective immune response
to the S-OIV H1N1 virus.Figure 3 Survival Rates and Body Weight Loss of immunized mice po
group) immunized with PBS, and 0.001 μg, 0.01 μg, and 0.05 μg of vaccine
with 106 TCID50 of A/California/7/2009 virus intranasally. Following 14 days
group are shown.Minimum dosage of the S-OIV H1N1 single-dose vaccine
required for generating protective immunity to a lethal
challenge of a/California/07/2009 H1N1
Since a single-dose vaccination can elicit an immune re-
sponse to S-OIV H1N1 virus, the minimum effective
dosage of S-OIV H1N1 vaccines was evaluated. Our pre-
vious data showed that a 0.5 μg to 0.1 μg dosage of
S-OIV H1N1 vaccine could provide mice with complete
protection against the virus (data not shown). Therefore,
groups of mice (n = 5 to 7) were immunized via the in-
traperitoneal (i.p.) route with different dosages of vac-
cine ranging from 0.05 μg to 0.001 μg in the absence or
presence of alum or MPLA adjuvant. Three weeks post
vaccination, the mice were bled and were challengedst challenge with A/California/7/2009 Virus. Mice (n = 4 to 7 per
with or without adjuvant (alum or MPLA), followed by lethal challenge
of observation, survival rates (A) and weight changes (B) in each
Figure 4 Adjuvant enhanced vaccine to elicit a
hemagglutination inhibition (HAI) antibody response.
Mice (n = 7 to 8 per group) were immunized with single different
dose of S-OIV H1N1 or NIBRG-14 H5N1 influenza vaccine with or
without alum or MPLA as the adjuvant. The titers of serum specific
antibodies were evaluated using the hemagglutination inhibition
(HAI) test. Data are representative of two separate experiments of
H1N1 vaccine immunized mice sera (No sera from H5N1-immunized
mice contained HAI to NIBRG-14 H5N1 virus using chicken red
blood cells). Comparisons of HAI antibody titer in mice immunized
with PBS, 0.001 μg, 0.1 μg, or 0.5 μg of HA in the produced vaccine
with or without adjuvant. For comparison of HAI antibody titers,
Student’s t test was used to examine the significance of differences
between HAI positive rates (with HAI titer 3 40) of each vaccinated
group and control group (mice immunized with PBS only). A P value
of < 0.05 was considered significant. The star “★” indicates
significant differences.
Lin et al. Journal of Biomedical Science 2013, 20:19 Page 8 of 13
http://www.jbiomedsci.com/content/20/1/19with A/California/07/2009 H1N1 virus one day later as
described in Materials and Methods. The body weight
and survival condition of the mice were recorded daily
for 14 days post challenge. The vaccine provided mice
protection in a dose-dependent manner (Figure 3A). MiceTable 2 HAI antibody titer of mice post immunized with S-OI
Adjuvant Sample dose 1 2 3 4 5
Pre-immune – – – – –
Non adjuvant PBS – – – – –
0.05 μg 80 160 – – –
0.01 μg 160 – – – –
0.001 μg – – – 40 –
Alum PBS – – – – –
0.05 μg 640 1280 80 640 12
0.01 μg 160 40 80 160 1
0.001 μg 80 – – – 4
MPLA PBS – – – – –
0.05 μg 160 320 320 – 1
0.01 μg 320 80 160 – 1
0.001 μg 80 – – –
*: Did not include into calculation because of failing to immunization.in the control group immunized with PBS had no protec-
tion. Single-dose vaccination of mice with the 0.05-μg can-
didate vaccine S-OIV H1N1 elicited sufficient protective
immunity to A/California/07/2009 H1N1 challenge.
Adjuvants reduced minimum protective dosages of both
S-OIV H1N1 and NIBRG-14 H5N1 influenza vaccines
Because a large amount of influenza vaccine could be re-
quired during a pandemic or epidemic of influenza virus,
an appropriate adjuvant should be considered as a com-
ponent of an influenza vaccine to reduce the vaccine
dosage for practical vaccination. In this study, alum and
MPLA adjuvants were evaluated and were compared for
their capabilities to reduce vaccine dosages required for
protecting mice from a lethal challenge of S-OIV H1N1
or NIBRG-14 H5N1 influenza virus. As shown in Table 2
and Figure 3A, 0.05 μg of S-OIV H1N1 vaccine was re-
quired to yield a 65% to 85.7% survival rate upon chal-
lenge with S-OIV H1N1 virus. When alum was included
as the adjuvant in the S-OIV H1N1 vaccine, the lowest
dosage of vaccine for complete protection of the mice
was reduced to 0.01 to 0.001 μg. Even when the mice
were vaccinated with 0.001 μg of S-OIV H1N1 vaccine
with alum, the survival rate was 66.67% (data not
shown). Furthermore, when the adjuvant included in the
vaccine was MPLA, the lowest dosage of S-OIV H1N1
vaccine providing mice complete protection from a le-
thal challenge of A/California/07/2009 H1N1 virus was
reduced to 0.001 μg. Meanwhile, body weight loss was
less significant when mice were immunized with vaccine
plus alum or MPLA adjuvants than with vaccine only
(Figure 3B upper panel). Body weight loss exceeded 25%
of the total pre-challenge weight for mice immunized
with PBS or vaccine only; while for mice immunized
with vaccine plus adjuvant, body weight loss was lessV H1N1 vaccine in the absence or presence of adjuvant
6 7 HAI ≥40 HAI titer Mean of HAI titer
– – 0/7 0 0
0/5 0 0
80 160 4/7 80 ~ 160 68.6
40 – 2/7 40 ~ 160 28.6
* – 1/6 40 6.7
– – 0/6 0 0
80 80 160 7/7 80 ~ 1280 594.3
60 80 320 7/7 80 ~ 320 142.9
0 80 80 4/7 40 ~ 80 40.0
– – 0/6 0 0
60 160 640 6/7 160 ~ 640 251.4
60 80 80 6/7 80 ~ 320 125.7
* 80 40 3/6 40 ~ 80 33.3
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http://www.jbiomedsci.com/content/20/1/19than 15%. Furthermore, the recovery of body weight was
more rapid for mice immunized with vaccine plus adju-
vant (the 5th day post challenge) than for mice immu-
nized with PBS or vaccine only (often the 7th or 9th day).
S-OIV H1N1 vaccine accompanied by an appropriate
adjuvant provided a protective effect in a single-dose
immunization regimen.MPLA adjuvant elicited cross-protective immunity to the
lethal challenge of homogeneous and heterogeneous
S-OIV H1N1 virus
Mice vaccinated with PBS or S-OIV H1N1 vaccine only
did not survive the challenge with S-OIV H1N1 influ-
enza virus (Figure 3A). Alum as an adjuvant provided
some protection for mice vaccinated with 0.01 μg (60%)
and 0.05 μg (80%) NIBRG-14 H5N1 vaccine upon chal-
lenged with a heterogeneous S-OIV H1N1 influenza
virus. In the presence of MPLA as the adjuvant, 0.01 μg
and 0.05 μg of the NIBRG-14 H5N1 vaccine provided
mice complete protection to the challenge of S-OIV
H1N1 influenza virus. Even vaccination with 0.001 μg of
NIBRG-14 H5N1 vaccine plus MPLA as the adjuvantFigure 5 Adjuvant promoted IgG responses of mice to homologous a
least immunization dose of S-OIV and H5N1 vaccine needed for mice to ra
H1N1 and NIBRG-14 H5N1 virus, mice (n = 3 to 4 per group) immunized w
3 weeks of single-dose immunization, mice sera were used to evaluate the
H5N1 virus, (C) H5N1 IgG to H1N1 virus, and (D) H1N1 IgG to H5N1 virus im
of antibodies in each group of animals.provided 40% survival to the challenge with S-OIV
H1N1 influenza virus. Furthermnore, mice vaccinated
with PBS or H5N1 vaccine alone died within 7 days
post challenge with A/California/07/2009 H1N1 virus
(Figure 3B lower panel). Mice vaccinated with NIBRG-
14 H5N1 plus alum or MPLA as the adjuvant lost 20%
to 40% or 10% to 30% of their body weight and then re-
covered 6 days or 7 to 8 days post challenge, respect-
ively. MPLA not only reduced the vaccine dosage
required for efficient protection from a homogeneous in-
fluenza virus, it also raised the survival rate of the lethal
challenge with the heterogeneous A/California/07/2009
H1N1 virus. A previous study revealed that the addition
of MPLA to the original vaccine increased CTL differen-
tiation, and these memory cells were better equipped to
rapidly kill infected cells than cells primed with alum
alone [28]; another study showed that MPLA induced
higher HAI antibody and IFNγ titers [18]. MPLA is a
TRIF-biased agonist of TLR4 and induces expression of
type I interferon through TRIF rather than MyD88 [29].
These results might be linked to the better protection
of MPLA as an adjuvant; however, this remains to
be elucidated.nd heterogeneous influenza H1N1 and H5N1 virus. To realize the
ise sufficient protective immune responses to A/California/7/2009
ith PBS, 0.01 μg, or 0.05 μg of vaccine with or without adjuvant. After
immune response type (A) H1N1 IgG to H1N1 virus, (B) H5N1 IgG to
mune responses. The data represent the mean titers ± SD (error bars)
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heterogeneous influenza H1N1 and H5N1 viruses
As influenza virus has antigen drift and antigen shift ef-
fects, vaccination with some influenza vaccine might not
induce sufficient immunity to the threat of other influ-
enza virus strains. In this study, we evaluated the cross
protection of S-OIV H1N1 and H5N1 influenza vaccine
in mice. Both alum and MPLA as adjuvants enhanced
H1N1 and H5N1 homologous IgG immune responses,
respectively (Figure 5A and 5B). Furthermore, the adju-
vants also promoted the production of heterogeneous
IgG immune responses: H5N1 IgG to S-OIV H1N1Figure 6 MPLA as the adjuvant significantly reduced lung viral titer. M
with or without different adjuvants. For the challenge, 106 TCID50 of virus w
lungs were homogenized and inoculated into MDCK cells for 48 h. Virus tit
H1N1 virus challenge, (B) H5N1 vaccination, H5N1 virus challenge, (C) H5N
challenge. The TCID50 titers of the virus were calculated by the method of
the differences in viral titers between two groups of vaccinated mice.influenza virus (Figure 5C) and H1N1 IgG to H5N1 in-
fluenza virus (Figure 5D). Alum used as the adjuvant
seemed to have a better effect than MPLA did for the in-
duction of these IgG immune responses.
MPLA as the adjuvant significantly reduced mice lung
viral titer post challenge with homologous and
heterogeneous influenza viruses
To evaluate the immune responses of immunized mice
to influenza virus, mice were vaccinated with S-OIV
H1N1 or NIBRG-14 H5N1 vaccines in the absence or
presence of different adjuvants. For the challenge, 106ice were vaccinated with S-OIV H1N1 or NIBRG-14 H5N1 vaccines
as inoculated into mice nasal cavities. Three days post challenge, mice
ers were evaluated using a micro-plaque assay. (A) H1N1 vaccination,
1 vaccination, H1N1 virus challenge, (D) H1N1 vaccination, H5N1 virus
Reed and Muench [reference 24]. P < 0.05 indicated the significance
Figure 7 Neutralization antibody response of immunized-mice post challenge with S-OIV H1N1 or NIBRG-14 H5N1 influenza virus.
Neutralization antibodies of mice post vaccinated with S-OIV H1N1 or NIBRG-14 H5N1 vaccines were evaluated using a microneutralization assay.
Mice sera (pre-immune as negative; A/California/7/2009 NIBSC 09/152 and antiserum to NIBRG-14 H5N1 HA as positive control) were mixed with
viruses (100 TCID50 of NIBRG-121 H1N1 or NIBRG-14 H5N1 virus) at room temperature for 1 hour, and were inoculated into 96-well MDCK cells
(1.5 × 104/ml). Experiments were performed following the WHO protocol for the microneutralization assay. (A) H1N1 vaccination, H1N1
neutralization antibody, (B) H5N1 vaccination, H5N1 neutralization antibody, (C) H5N1 vaccination, H1N1 neutralization antibody, (D) H1N1
vaccination, H5N1 neutralization antibody. Error bar is the standard deviation of six serum samples.
Lin et al. Journal of Biomedical Science 2013, 20:19 Page 11 of 13
http://www.jbiomedsci.com/content/20/1/19TCID50 influenza viruses were inoculated into the nasal
cavities of the mice. The lungs of the mice were
harvested and homogenized three days after inoculation
and then, inoculated into MDCK cells and incubated for48 h. Virus titers were evaluated using a micro-plaque
assay. As shown in Figure 6A, 0.05 μg of S-OIV H1N1
vaccine significantly reduced mouse lung H1N1 viral ti-
ters; the adjuvant promoted vaccine-induced reduction
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ters, the vaccine alone had no significant effect; on the
other hand, in the presence of either alum or MPLA,
even 0.01 μg of NIBRG-14 H5N1 vaccine significantly
reduced the lung H5N1 viral titer (Figure 6B).
To evaluate cross-protection of vaccines to S-OIV
H1N1 and NIBRG-14 H5N1 influenza viruses, lung viral
titers were measured in mice vaccinated with S-OIV
H1N1 or NIBRG-14 H5N1 vaccines in the absence or
presence of alum or MPLA included as adjuvants.
NIBRG-14 H5N1 vaccine alone did not significantly re-
duce H1N1 viral titers in the mouse lungs (Figure 6C),
where 0.01 μg of NIBRG-14 H5N1 vaccine plus MPLA
significantly reduced the lung H1N1 viral titers. Con-
versely, S-OIV H1N1 vaccine, even with alum or MPLA
adjuvant, did not significantly reduce mouse lung H5N1
viral titers post challenge (Figure 6D). Thus, the avian
NIBRG-14 H5N1 might provide some cross-protection to
S-OIV H1N1 virus in mice, but not vice versa. In a similar
study, cross-protection of seasonal influenza virus and
2009 pandemic H1N1 influenza virus in mice and ferrets
showed that vaccination with the seasonal influenza
vaccines did not confer complete protection in the lower
respiratory tract in either animal model, whereas the A/
California/7/2009 vaccine conferred complete protection
in both animal models [30]. In our study, only the MPLA
adjuvant in the NIBRG-14 H5N1 vaccine reduced the het-
erogeneous S-OIV H1N1 lung viral titer. The underlying
mechanisms remain to be elucidated.Adjuvant elicited homologous but not heterogeneous
neutralization antibody against influenza virus
Neutralization antibody always plays an important role in
the evaluation of host immunity after vaccination for influ-
enza viruses. We evaluated the roles of adjuvants in the
vaccines to elicit neutralization antibody. H1N1 and H5N1
vaccines with alum or MPLA adjuvant elicited significantly
more homologous neutralization antibodies to S-OIV
H1N1 and H5N1 influenza virus, respectively, than vaccine
alone (Figure 7A and 7C). Alum enhanced the production
of neutralization antibody against homologous influenza
virus, but none of adjuvants induced production of hetero-
geneous neutralizing antibody (Figure 7B and 7D).
Our results indicate that a significant reduction of in-
fluenza viral titer in lungs of mice three days post chal-
lenge was a better indicator for survival prediction than
hemagglutination inhibition (HAI) and neutralization
antibody titers. Alum and MPLA used as adjuvants re-
duce the vaccine dosage requirement and elicit protect-
ive immunity to homologous influenza virus. MPLA
further promoted vaccine cross-protection in mice vac-
cinated with NIBRG-14 H5N1 to lethal challenge with
heterogeneous S-OIV H1N1 influenza virus.Conclusion
The study results showed that a single-dose immunization
in BALB/c mice with 0.1 μg of the candidate vaccine elic-
ited complete protective immunity to S-OIV H1N1 virus.
This result is consistent with a previous study [16]; this
minimal effective vaccine dose in BALB/c mice corre-
sponds to approximately 30 μg of HA in humans. Further-
more, we also learned that when the vaccine contained an
appropriate amount of MPLA adjuvant, the vaccine elic-
ited protective immunity to S-OIV H1N1 with single-dose
immunization using 1/100 to 1/10 of the original vaccine
dosage (corresponding to approximately 0.3 to 3 μg of HA
in humans). Additionally, both H1N1 and H5N1 induced
significant homologous, but not heterogeneous neutra-
lization antibody. Only in the presence of adjuvant could
the influenza vaccine protect mice from a lethal challenge
of heterogeneous influenza virus. MPLA as the adjuvant
with H5N1 vaccine significantly reduced lung H1N1 virus
titers post challenge in the mice. Results revealed that lung
viral titer was a better indicator than IgG, HAI, and
neutralization antibodies titer, in predicting survival rates
of mice post influenza virus challenge. Results from this
study revealed (1) the minimum protective vaccination
dosage; (2) the single-dose vaccination regimen induced
protective immunity in the presence of adjuvant; (3)
cross-protection evaluation between S-OIV H1N1 and
NIBRG-14 H5N1 vaccines; (4) adjuvant promoted anti-
viral protection and reduce the required vaccination
dosage; and (5) MPLA as the adjuvant promoted better
cross-protection of NIBRG-14 H5N1 vaccine to the lethal
challenge with the 2009 pandemic H1N1 influenza virus,
possibly through Th1 immunity. These data provide im-
portant insight for the design and development of vaccine
formulas and adjuvants.
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